Mueller, Roman-Ulrich;
Messchendorp, A Lianne;
Birn, Henrik;
Capasso, Giovambattista;
Cornec-Le Gall, Emilie;
Devuyst, Olivier;
van Eerde, Albertien;
... Gansevoort, Ron T; + view all
(2021)
An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International.
Nephrology Dialysis Transplantation
10.1093/ndt/gfab312.
(In press).
Preview |
Text
gfab312.pdf - Published Version Download (967kB) | Preview |
Abstract
The approval of the vasopressin V2-receptor antagonist tolvaptan - based on the landmark TEMPO 3:4 trial - has marked a transformation in the management of autosomal dominant polycystic kidney disease (ADPKD). This development has advanced patient care in ADPKD from general measures to prevent progression of chronic kidney disease to targeting disease specific mechanisms. However, considering the long-term nature of this treatment as well as potential side effects, evidence-based approaches to initiate treatment only in patients with rapidly progressing disease are crucial. In 2016, the position statement issued by the ERA was the first society-based recommendation on the use of tolvaptan and has served as a widely-used decision-making tool for nephrologists. Since then, considerable practical experience regarding the use of tolvaptan in ADPKD has accumulated. More importantly, additional data from REPRISE, a second randomized clinical trial (RCT) examining the use of tolvaptan in later stage disease has added important evidence to the field, as have post-hoc studies of these RCTs. To incorporate this new knowledge, we provide an updated algorithm to guide patient selection for treatment with tolvaptan and add practical advice for its use.
| Type: | Article |
|---|---|
| Title: | An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1093/ndt/gfab312 |
| Publisher version: | https://doi.org/10.1093/ndt/gfab312 |
| Language: | English |
| Additional information: | © The Author(s) 2021. Published by Oxford University Press on behalf of the ERA. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Transplantation, Urology & Nephrology, ADPKD, polycystic kidney disease, position statement, tolvaptan, vasopressin V2 receptor antagonist, PROGRESSION, ANTAGONIST, BIOMARKERS, MANAGEMENT, VESICLES, EQUATION, TRIALS, SALT |
| UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Renal Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10146102 |
Archive Staff Only
 |
View Item |
